Pemafibrate

• Description:

  Pemafibrate is a highly selective PPARα agonist, with an EC50 of 1 nM.

• Product Name Alternative:

  (R) -K-13675

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Pemafibrate.html

• Purity:

  99.88

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CC[C@@H](OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(OC)C=C4)=C1)C(O)=O

• Molecular Formula:

  C28H30N2O6

• Molecular Weight:

  490.55

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Yamazaki Y, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett. 2007 Aug 15;17 (16) :4689-93. Epub2007 May 24.|[2]Honda Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017 Feb 14;7:42477.|[3]Sairyo M, et al. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb. 2018 Feb 1;25 (2) :142-152.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  PPARα; PPARβ/δ; PPARγ

• CAS Number:

  [848259-27-8]